Cancer Science Institute of Singapore, National University of Singapore, Singapore.
Gut. 2014 May;63(5):832-43. doi: 10.1136/gutjnl-2012-304037. Epub 2013 Jun 13.
Hepatocellular carcinoma (HCC) is a heterogeneous tumour displaying a complex variety of genetic and epigenetic changes. In human cancers, aberrant post-transcriptional modifications, such as alternative splicing and RNA editing, may lead to tumour specific transcriptome diversity.
By utilising large scale transcriptome sequencing of three paired HCC clinical specimens and their adjacent non-tumour (NT) tissue counterparts at depth, we discovered an average of 20 007 inferred A to I (adenosine to inosine) RNA editing events in transcripts. The roles of the double stranded RNA specific ADAR (Adenosine DeAminase that act on RNA) family members (ADARs) and the altered gene specific editing patterns were investigated in clinical specimens, cell models and mice.
HCC displays a severely disrupted A to I RNA editing balance. ADAR1 and ADAR2 manipulate the A to I imbalance of HCC via their differential expression in HCC compared with NT liver tissues. Patients with ADAR1 overexpression and ADAR2 downregulation in tumours demonstrated an increased risk of liver cirrhosis and postoperative recurrence and had poor prognoses. Due to the differentially expressed ADAR1 and ADAR2 in tumours, the altered gene specific editing activities, which was reflected by the hyper-editing of FLNB (filamin B, β) and the hypo-editing of COPA (coatomer protein complex, subunit α), are closely associated with HCC pathogenesis. In vitro and in vivo functional assays prove that ADAR1 functions as an oncogene while ADAR2 has tumour suppressive ability in HCC.
These findings highlight the fact that the differentially expressed ADARs in tumours, which are responsible for an A to I editing imbalance, has great prognostic value and diagnostic potential for HCC.
肝细胞癌(HCC)是一种表现出复杂遗传和表观遗传变化的异质性肿瘤。在人类癌症中,异常的转录后修饰,如选择性剪接和 RNA 编辑,可能导致肿瘤特异性转录组多样性。
通过利用三个配对 HCC 临床标本及其相邻非肿瘤(NT)组织对照的大规模转录组测序深度,我们在转录本中发现了平均 20007 个推断的 A 到 I(腺苷到肌苷)RNA 编辑事件。在临床标本、细胞模型和小鼠中研究了双链 RNA 特异性 ADAR(Adenosine DeAminase that act on RNA)家族成员(ADARs)的作用和改变的基因特异性编辑模式。
HCC 显示出严重破坏的 A 到 I RNA 编辑平衡。ADAR1 和 ADAR2 通过在 HCC 与 NT 肝组织中的差异表达来操纵 HCC 的 A 到 I 失衡。在肿瘤中 ADAR1 过表达和 ADAR2 下调的患者,肝硬化和术后复发的风险增加,预后不良。由于肿瘤中差异表达的 ADAR1 和 ADAR2,改变的基因特异性编辑活性,反映在 FLNB(肌动蛋白 B,β)的高编辑和 COPA(衣壳蛋白复合物,亚基α)的低编辑,与 HCC 的发病机制密切相关。体外和体内功能测定证明 ADAR1 作为癌基因,而 ADAR2 在 HCC 中具有肿瘤抑制能力。
这些发现强调了这样一个事实,即肿瘤中差异表达的 ADARs 负责 A 到 I 编辑失衡,对 HCC 具有重要的预后价值和诊断潜力。